KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Change in Accured Expenses (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Change in Accured Expenses data on record, last reported at $168.7 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 5541.94% year-over-year to $168.7 million; the TTM value through Dec 2025 reached $395.1 million, up 341.45%, while the annual FY2025 figure was $395.1 million, 341.45% up from the prior year.
  • Change in Accured Expenses reached $168.7 million in Q4 2025 per EW's latest filing, down from $226.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $226.1 million in Q3 2025 and bottomed at -$109.2 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $40.2 million, with a median of $32.2 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: crashed 1074.19% in 2022, then surged 5541.94% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $31.1 million in 2021, then grew by 10.29% to $34.3 million in 2022, then dropped by 2.62% to $33.4 million in 2023, then plummeted by 109.28% to -$3.1 million in 2024, then soared by 5541.94% to $168.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $168.7 million in Q4 2025, $226.1 million in Q3 2025, and $103.7 million in Q2 2025.